0001193125-21-025540.txt : 20210305 0001193125-21-025540.hdr.sgml : 20210305 20210202112558 ACCESSION NUMBER: 0001193125-21-025540 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Terns Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001831363 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1065 EAST HILLSDALE BLVD., SUITE 100 CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 650-525-5535 EXT.101 MAIL ADDRESS: STREET 1: 1065 EAST HILLSDALE BLVD., SUITE 100 CITY: FOSTER CITY STATE: CA ZIP: 94404 CORRESP 1 filename1.htm CORRESP

Terns Pharmaceuticals, Inc.

1065 East Hillsdale Blvd., Suite 100

Foster City, California 94404

February 2, 2021

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549-6010

 

Attention:

David Burton

 

Sasha Parikh

 

Chris Edwards

 

Celeste Murphy

 

  Re:

Terns Pharmaceuticals, Inc.

   

Registration Statement on Form S-1 (Registration No. 333-252180)

 

Ladies and Gentlemen:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-252180) (the “Registration Statement”) of Terns Pharmaceuticals, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on February 4, 2021, or as soon as practicable thereafter, or at such other time as our legal counsel, Latham & Watkins LLP, may request by telephone to the staff of the U.S. Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Brian Cuneo at (650) 463-3014 or Michael Podolny at (650) 470-4984.

Under separate cover, you will receive today a letter from the managing underwriters of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement.

Thank you for your assistance in this matter.

 

Very truly yours,
TERNS PHARMACEUTICALS, INC.
By:   /s/ Senthil Sundaram
  Senthil Sundaram
  Chief Executive Officer

 

CC:

Bryan Yoon, Terns Pharmaceuticals, Inc.

 

Nathan Ajiashvili, Latham & Watkins LLP

 

Brian Cuneo, Latham & Watkins LLP

 

Michael Podolny, Latham & Watkins LLP

 

Yasin Keshvargar, Davis Polk & Wardwell LLP

 

Alan F. Denenberg, Davis Polk & Wardwell LLP